The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
Open accessAbstract
A pro-inflammatory intestinal microbiome is characteristic of Parkinson’s disease (PD). Prebiotic fibers change the microbiome and this study sought to understand the utility of prebiotic fibers for use in PD patients. The first experiments demonstrate that fermentation of PD patient stool with prebiotic fibers increased the production of beneficial metabolites (short chain fatty acids, SCFA) and changed the microbiota demonstrating the capacity of PD microbiota to respond favorably to prebiotics. Subsequently, an open-label, non-randomized study was conducted in newly diagnosed, non-medicated ( n = 10) and treated PD participants ( n = 10) wherein the impact of 10 days of prebiotic intervention was evaluated. Outcomes demonstrate that the prebiotic intervention was well tolerated (primary outcome) and safe (secondary outcome) in PD participants and was associated with beneficial biological changes in the microbiota, SCFA, inflammation, and neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept study offers the scientific rationale for placebo-controlled trials using prebiotic fibers in PD patients. ClinicalTrials.gov Identifier: NCT04512599.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A proof-of-concept trial conducted in PD patients has demonstrated that SCFAs-promoting prebiotic fiber intervention reduced plasma zonulin, indicating improved intestinal barrier integrity.”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [332]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is limited evidence of how pre- and pro-biotics influence gut microbiome composition and functionality, with only limited evidence from a few open-label studies to suggest that pre- and pro-biotics can increase the abundance of SCFA-producing bacteria, reduce the abundance of pro-inflammatory bacteria, and reduce levels of intestinal inflammatory markers like calprotectin [163, 177].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [177]
Experimental — accuracy not yet measuredIn the citing paper
“Importantly, the trial reported an increased abundance of SCFAs-producing species and increased plasma SCFA levels, along with improved intestinal barrier integrity and reduced intestinal inflammation.332”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [332]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,757
da Luz, A. C. D. D. S., Dias, G. P., Bevilaqua, M. C. D. N., Cocks, G. D., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 4,015
Interaction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947
Distance‐Based Tests for Homogeneity of Multivariate Dispersions
Anderson, M. J. (2006) · Biometrics · doi:10.1111/j.1541-0420.2005.00440.x · Cited by 3,304
Beghini, F., McIver, L. J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S., Mailyan, A., Manghi, P., Scholz, M., Thomas, A. M., et al. (2021) · eLife · doi:10.7554/elife.65088 · Cited by 2,303
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Cited by
Sorted by citations
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Probiotics, prebiotics, and postbiotics in health and disease
Ji, J., Jin, W., Liu, S., Jiao, Z., & Li, X. (2023) · MedComm · doi:10.1002/mco2.420 · Cited by 449
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 212
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 99
An Update on Prebiotics and on Their Health Effects
Bevilacqua, A., Campaniello, D., Speranza, B., Racioppo, A., Sinigaglia, M., & Corbo, M. R. (2024) · Foods · doi:10.3390/foods13030446 · Cited by 97
Liu, X., Liu, Y., Liu, J., Zhang, H., Shan, C., Guo, Y., Gong, X., Cui, M., Li, X., & Tang, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.382223 · Cited by 75
Ma, Z., Wang, Z., Cao, J., Dong, Y., & Chen, Y. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2560019 · Cited by 70
The Gut–Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics
Saxami, G., Kerezoudi, E. N., Eliopoulos, C., Arapoglou, D., & Kyriacou, A. (2023) · Life · doi:10.3390/life13102023 · Cited by 65
Precision microbiota therapy for IBD: premise and promise
Nagayama, M., Gogokhia, L., & Longman, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2489067 · Cited by 58
Gastrointestinal disorders in Parkinson’s disease and other Lewy body diseases
Hirayama, M., Nishiwaki, H., Hamaguchi, T., & Ohno, K. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00511-2 · Cited by 51
Menozzi, E., & Schapira, A. H. V. (2024) · CNS Drugs · doi:10.1007/s40263-024-01073-4 · Cited by 50
Fołta, J., Rzepka, Z., & Wrześniok, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115177 · Cited by 50
The Brain–Gut–Bone Axis in Neurodegenerative Diseases: Insights, Challenges, and Future Prospects
Li, R., Miao, Z., Liu, Y., Chen, X., Wang, H., Su, J., & Chen, J. (2024) · Advanced Science · doi:10.1002/advs.202307971 · Cited by 54
The Role of Diet in Parkinson’s Disease
Tosefsky, K. N., Zhu, J., Wang, Y. N., Lam, J. S. T., Cammalleri, A., & Appel‐Cresswell, S. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230264 · Cited by 50
Microbiome-based therapies for Parkinson’s disease
Alam, M., Abbas, K., Mustafa, M., Usmani, N., & Habib, S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1496616 · Cited by 46
Past, present, and future of microbiome-based therapies
Manrique, P., Montero, I., Fernández-Gosende, M., Martínez, N., Hidalgo-Cantabrana, C., & Ríos-Covián, D. (2024) · Microbiome Research Reports · doi:10.20517/mrr.2023.80 · Cited by 42
Butyrate as a potential therapeutic agent for neurodegenerative disorders
Chakraborty, P., Gamage, H. K. A. H., & Laird, A. S. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105745 · Cited by 44
Ghassab, F. T., Mahmoudi, F. S., Tinjani, R. T., Meibodi, A. E., Zali, M. R., & Yadegar, A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122748 · Cited by 40
Choe, U. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106870 · Cited by 48
The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
Menozzi, E., Schapira, A. H. V., & Borghammer, P. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70029 · Cited by 42
Ristori, S., Bertoni, G., Bientinesi, E., & Monti, D. (2025) · Nutrients · doi:10.3390/nu17111837 · Cited by 43
Modulation of gut microbiome in the treatment of neurodegenerative diseases: A systematic review
Mincic, A. M., Antal, M., Filip, L. A., & Miere, D. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.05.036 · Cited by 41
The gut–brain axis in early Parkinson’s disease: from prodrome to prevention
Oliver, P. J., Civitelli, L., & Hu, M. T. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13138-5 · Cited by 42
“…functionality, with only limited evidence from a few open-label studies to suggest that pre-and pro-biotics can increase the abundance of SCFA-producing bacteria, reduce the abundance of pro-inflammatory bacteria, and reduce levels of intestinal inflammatory markers like calprotectin [163, 177].”
Park, D. G., Kang, W., Shin, I.-J., Chalita, M., Oh, H.-S., Hyun, D.-W., Kim, H., Chun, J., An, Y.-S., Lee, E. J., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106655 · Cited by 34
Safarpour, D., Stover, N. P., Shprecher, D., Hamedani, A. G., Pfeiffer, R. F., Parkman, H. P., Quigley, E. M. M., & Cloud, L. J. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106982 · Cited by 32
The emerging role of microbiota derived SCFAs in neurodegenerative disorders
Wachamo, S., & Gaultier, A. (2025) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2025.101012 · Cited by 36
Taj, T., Kaushik, M., Islam, A., Das, J., Kumar, B., Hussain, M. S., Ramzan, M., Ashique, S., Tariq, M., Sridhar, S. B., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118861 · Cited by 35
Gut microbiota and Parkinson’s disease
Wang, L., Cui, Y., Han, B., Du, Y., Salewala, K. S., Wang, S., Zhao, W., Zhang, H., Wang, S., Xu, X., et al. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003318 · Cited by 31
Mediterranean Diet Adherence, Gut Microbiota and Parkinson’s Disease: A Systematic Review
Seelarbokus, B. A., Menozzi, E., Schapira, A. H. V., Kalea, A. Z., & Macnaughtan, J. (2024) · Nutrients · doi:10.3390/nu16142181 · Cited by 36
Microbiome-based therapeutics for Parkinson's disease
Hamilton, A. M., Krout, I. N., White, A. C., & Sampson, T. R. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00462 · Cited by 31
Bedarf, J. R., Romano, S., Heinzmann, S. S., Duncan, A., Τράκα, Μ., Ng, D. Y. K., Segovia-Lizano, D., Simon, M., Narbad, A., Wüllner, U., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00885-5 · Cited by 32
The gut microbiome, systemic inflammation, and autoimmunity in Parkinson's disease
Fonseca, M. D. C., Zanetti, L., Fanourakis, S., Sulzer, D., & Mazmanian, S. K. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00382-5 · Cited by 29
Scuto, M. C., Anfuso, C. D., Lombardo, C., Fatta, E. D., Ferri, R., Musso, N., Zerbo, G., Terrana, M., Majzúnová, M., Lupo, G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199391 · Cited by 31
Buty and the beast: the complex role of butyrate in Parkinson’s disease
Elford, J. D., Becht, N. N., Garssen, J., Kraneveld, A. D., & Perez‐Pardo, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1388401 · Cited by 28
Hegelmaier, T., Duscha, A., Desel, C., Fuchs, S., Shapira, M., Amidror, S., Shan, Q., Stangl, G. I., Hirche, F., Kempa, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-29692-x · Cited by 31
The interplay between gut microbiota and the brain-gut axis in Parkinson’s disease treatment
Jia, X., Wang, Q., Liu, M., & Ding, J.-Y. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1415463 · Cited by 26
Systematically-designed mixtures outperform single fibers for gut microbiota support
Cantu-Jungles, T. M., Agamennone, V., van den Broek, T. J., Schuren, F. H. J., & Hamaker, B. R. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2442521 · Cited by 28
Self-citationWang, J., Xue, L., Zhang, M., Shen, P., Zhao, W., Tong, Q., Wu, S.-N., Dai, W., Yang, X., & Wang, H. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106086 · Cited by 25
The link between the gut microbiome, inflammation, and Parkinson’s disease
Nie, S., & Ge, Y. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12789-6 · Cited by 23
Kumar, D., Bishnoi, M., Kondepudi, K. K., & Sharma, S. S. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10433-x · Cited by 22
Admasu, F., Fentie, E. G., Admassu, H., & Shin, J. (2024) · LWT · doi:10.1016/j.lwt.2024.116182 · Cited by 20
Yang, Y. X., Xu, Z., Guo, J., Xiong, Z., & Hu, B. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100763 · Cited by 23
Peng, Z., Hou, T., Yang, K., Zhang, J., Mao, Y.-H., & Hou, X. (2025) · Nutrients · doi:10.3390/nu17111769 · Cited by 21
Marzouk, N. H., Rashwan, H. H., El-Hadidi, M. S., Ramadan, R., & Mysara, M. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00950-z · Cited by 21
Prebiotics, Probiotics and Postbiotics: The Changing Paradigm of Functional Foods
Kango, N., & Nath, S. (2024) · Journal of Dietary Supplements · doi:10.1080/19390211.2024.2363199 · Cited by 27
The Role of the Gastrointestinal Microbiota in Parkinson’s Disease
Gabrielli, M., Verme, L. Z. D., Zocco, M. A., Nista, E. C., Ojetti, V., & Gasbarrini, A. (2024) · Biomolecules · doi:10.3390/biom15010026 · Cited by 19
The Mediating Role of Bioactive Molecules in Gut Microbiota–Bone Metabolism Crosstalk
Liang, X., & Wang, L. (2025) · Nutrients · doi:10.3390/nu17213421 · Cited by 19
Zhou, S., Zhou, H., Jia, Q., Han, J., Zhang, Y., Li, Y., Zhang, M., & Cong, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132362 · Cited by 17
Parkinson Disease and the Gut: A Primer for Gastroenterologists
Sharma, A., Voigt, R. M., Goetz, C. G., & Keshavarzian, A. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003508 · Cited by 17
Self-citationPharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease
Zhang, Y., Mo, C., Ai, P., He, X., Xiao, Q., & Yang, X. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2454937 · Cited by 20
Nootropic foods in neurodegenerative diseases: mechanisms, challenges, and future
Nguyen, L. A. M., Simons, C. W., & Thomas, R. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00476-7 · Cited by 18
Hajare, S., & Kulkarni, Y. A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149975 · Cited by 18
Yang, Y., Wang, Q., Wang, Z., Wang, Y., Liu, B., Zhang, Y., Mao, X., & Sun, H. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100944 · Cited by 21
Deng, F., Yang, D., Qing, L., Chen, Y., Zou, J., Jia, M., Wang, Q., Jiang, R., & Li-hua, H. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00607 · Cited by 19
Koumpouli, D., Koumpouli, V., & Koutelidakis, A. Ε. (2025) · Applied Sciences · doi:10.3390/app15105558 · Cited by 16
Modulation of Gut Microbiota by the Complex of Caffeic Acid and Corn Starch
Yu, M., Bulut, N., Zhao, X., Rivera, R. J. L., Li, Y., & Hamaker, B. R. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c06946 · Cited by 14
Self-citationPeters, M., Hegelmaier, T., Wegner, F., Höllerhage, M., Ye, L., Niesmann, C., Schneidereit, I. V., Haghikia, A., & Klietz, M. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13545-8 · Cited by 14
Yao, L., Yang, Y., Yang, X., & Rezaei, M. J. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04151-2 · Cited by 15
Voigt, R. M., Engen, P. A., Villanueva, M., Bambi, S. A., Green, S. J., Naqib, A. D., Raeisi, S., Shaikh, M. W., Hamaker, B. R., Cantu-Jungles, T. M., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1477519 · Cited by 14
Self-citationLewy body diseases and the gut
Sampson, T. R., Tansey, M. G., West, A. B., & Liddle, R. A. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00804-5 · Cited by 13
Ekwudo, M. N., Masson, B. A., Natale, M. R. D., Kiridena, P., van de Garde, N., Lei, E., Sarkar, S. K., Narayana, V. K., Renoir, T., Furness, J. B., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106074 · Cited by 11
Gut-directed therapy in Parkinson’s disease
Benvenuti, L., Salvo, C. D., Bellini, G., Seguella, L., Rettura, F., Esposito, G., Antonioli, L., Ceravolo, R., Bernardini, N., Pellegrini, C., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1407925 · Cited by 13
Renesteen, E., Boyajian, J. L., Islam, P., Kassab, A., Abosalha, A. K., Makhlouf, S., Santos, M., Chen, H., Shum-Tim, C., & Prakash, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115351 · Cited by 11
The role of the gut microbiota in neuropsychiatric disorders and therapy
Zhang, F., Ding, K., Zhang, L., Liu, D., Dong, X., Wang, M., Zhou, F.-L., Sun, Y., Zhang, W., Yu, Y., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102894 · Cited by 11
Jin, X., Wei, J., Min, X., Fan, Y., Yuan, Z., Du, Z., Su, Z., Xun, T., Du, Q., Liang, T., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114185 · Cited by 15
Hansen, B., Laczny, C. C., Aho, V. T. E., Frachet-Bour, A., Habier, J., Ostaszewski, M., Michalsen, A., Hanslian, E., Koppold, D. A., Hartmann, A. M., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071380 · Cited by 10
Modulation of Gut Microbiome as a Therapeutic Modality for Auditory Disorders
Godur, D. A., Denton, A. J., Eshraghi, N., Mittal, J., Cooper, J. N., Moosa, M., & Mittal, R. (2023) · Audiology Research · doi:10.3390/audiolres13050066 · Cited by 10
Advice to People with Parkinson’s in My Clinic: Probiotics and Prebiotics
Hor, J. W., Toh, T. S., Lim, S., & Tan, A. H. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240172 · Cited by 9
Prebiotic potential of spent brewery grain – In vitro study
Kruk, M., Lalowski, P., Płecha, M., Ponder, A., Dudkiewicz, A., Zielińska, D., & Trząskowska, M. (2024) · Food Chemistry · doi:10.1016/j.foodchem.2024.141254 · Cited by 10
Nutritional and dietary clinical trials for Parkinson's disease: a narrative review
Giannakis, A., Chondrogiorgi, M., Konitsiotis, S., & Sidiropoulos, C. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02901-7 · Cited by 11
Effects of enteral nutrition in stroke: an updated review
Jiang, D., Nie, L., Xiang, X., Guo, X., Qin, M., Wang, S., Chen, J., Feng, Y., Huang, M., & Mao, L. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1510111 · Cited by 13
Chen, X., Zhang, Y., Chen, T., Ji, H., Liu, J., Yang, L., Zhang, L., Xie, P., Zhou, Q., & Wan, H. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100024 · Cited by 8
Self-citationUnveiling Butyrate as a Parkinson’s Disease Therapy
Abreu, A. E., Empadinhas, N., & Cardoso, S. M. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01498-x · Cited by 7
Fan, Y., Xiao, B., Zhou, H., Liu, Z., Wang, L., Jin, W., Yin, Y., & Mao, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108031 · Cited by 7
Lifestyle medicine in Parkinson’s disease
Süß, P., Regensburger, M., Gassner, H., & Winkler, J. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03059-y · Cited by 6
Петров, В. А., Schade, S., Laczny, C. C., Hällqvist, J., May, P., Jäger, C., Aho, V. T. E., Hickl, O., Halder, R., Lang, E., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106217 · Cited by 6
Zhang, F., Liu, Y., Zhu, Y., Yu, Q.-Y., Msigwa, S. S., Zeng, Z.-H., Zhang, X., Wu, H.-M., & Zhu, J. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.01.028 · Cited by 7
Li, X., Hao, X., Chen, C., Zhai, C., Pan, T., Zhou, X., Liu, Y., Wu, D., & Chen, X. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1421270 · Cited by 7
Therapeutic role of probiotics in motor and non-motor symptoms of Parkinson’s disease
Páez‐García, S., Hernández-Triana, D., Salazar, F. E., Barreto, G. E., Rodríguez-Oroz, M. C., & Borda, M. G. (2025) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2025.1004129 · Cited by 3
Mendonça, I. P., da Silva, R. S., de Paiva, I. H. R., Costa, B. L. D. S. A., Teixeira, K. P. D. S. B., de Souza, J. R. B., & Peixoto, C. A. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02152-2 · Cited by 3
Bhardwaj, K., Singh, A. A., & Kumar, H. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00293 · Cited by 4
Role of the Intestinal Microbiota in the Molecular Pathogenesis of Atypical Parkinsonian Syndromes
Przewodowska, D., Alster, P., & Madetko‐Alster, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093928 · Cited by 4
Sleep deprivation and risk for Parkinson’s disease: evidence and therapeutic implications
Zhou, T., Ye, W., Chen, B., Zhu, L., Wang, Z., Mao, J.-F., Wu, W., Li, Y., & Wu, H. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13407-3 · Cited by 2
Gut Microbiota and Dopamine: Producers, Consumers, Enzymatic Mechanisms, and In Vivo Insights
Albani, G., Chellamuthu, V. R., Morlacchi, L., Zirone, F., Youssefi, M., Giardini, M., Chao, Y., Tan, E., & Albani, S. (2025) · Bioengineering · doi:10.3390/bioengineering13010055 · Cited by 5
Zhang, Y., Chen, L., Jin, J., Xin, Y., Wang, J., & Zhang, A. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115631 · Cited by 2
Cabanillas-Lazo, M., Pascual-Guevara, M., Chavez‐Ecos, F. A., Alva-Diaz, C., Velásquez‐Rimachi, V., Mori, N., & Micheli, F. E. (2026) · Gerontology · doi:10.1159/000547665 · Cited by 2
Gut Microbiota: Role in Health and Diseases
Bhardwaj, K., Das, B., Zuo, T., & Vrati, S. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1007004 · Cited by 2
Microbiome-based biomarkers to guide personalized microbiome-based therapies for Parkinson’s diseasePreprint
Payami, H., Sampson, T. R., Murchison, C., & Wallen, Z. D. (2024) · medRxiv · doi:10.1101/2024.04.03.24305273 · Cited by 3
Sahran, N., Chong, C. W., Ismail, I. H., Taib, F., Hoo, P. S., Palanisamy, U. D., Sundralingam, U., Teh, C. S. J., Kong, Z.-X., Ayub, Q., et al. (2025) · Beneficial Microbes · doi:10.1163/18762891-bja00074 · Cited by 2
“Unfolding Parkinson’s Disease Through the Microbiome-Gut-Brain Axis”
Shenthilvel, R. K., Thangavelu, A. U., Uvarajan, D., Mathuraj, M., & Ravikumar, M. (2026) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02462-0 · Cited by 1
Advances in the pharmacological management of early motor manifestations of Parkinson’s disease (PD)
Müller, T. H., & Kohlhepp, W. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2645845 · Cited by 1
Ravi, A., & Pan, I. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.108989 · Cited by 1
Using gut neuron health as a predictive indicator of neurodegenerative disease
Langerová, T., & Gregory, J. M. (2026) · Future Neurology · doi:10.1080/14796708.2026.2684938 · Cited by 1
The gut microbiome and colorectal cancer
Dietz, M. A., Subramanian, S., & Staley, C. M. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00332-25 · Cited by 1
Zusammenhänge zwischen Mikrobiom und Neurodegeneration
Bang, C., & Heinzel, S. (2023) · Der Nervenarzt · doi:10.1007/s00115-023-01537-w · Cited by 1
Use of a Novel Passive E-Nose to Monitor Fermentable Prebiotic Fiber Consumption
Kosinski, L. R., Engen, P. A., Swanson, B. A., Villanueva, M., Shaikh, M. W., Green, S. J., Naqib, A. D., Hamaker, B. R., Cantu-Jungles, T. M., & Keshavarzian, A. (2025) · Sensors · doi:10.3390/s25030797 · Cited by 1
Self-citationMicrobiome-Based Therapeutics: Emerging Trends in Health Biotechnology
Ullah, I., & Yasmin, M. (2024) · Premier journal of science. · doi:10.70389/pjs.100022 · Cited by 2
Supplementation with short-chain fatty acids and the prebiotic 2FL improves clinical outcome in PDPreprint
Hegelmaier, T., Duscha, A., Desel, C., Fuchs, S., Shapira, M., Shan, Q., Stangl, G. I., Hirche, F., Kempa, S., Maifeld, A., et al. (2023) · medRxiv · doi:10.1101/2023.11.01.23297866 · Cited by 1
Murchison, C., Antonello, G., Wallen, Z. D., Dean, M. N., Verster, A. J., Long, K., Waldron, L., Sampson, T. R., Standaert, D. G., & Payami, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.12.724602 · Cited by 1
Lee, E. J., Park, D. G., Kang, W., Shin, I.-J., Chalita, M., Oh, H., Hyun, D., Kim, H., Chun, J., An, Y., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3742244/v1
Metadata
- Authors
- Hall, D. A., Voigt, R. M., Cantu-Jungles, T. M., Hamaker, B., Engen, P. A., Shaikh, M., Raeisi, S., Green, S. J., Naqib, A., Forsyth, C. B., Chen, T., Manfready, R., Ouyang, B., Rasmussen, H. E., Sedghi, S., Goetz, C. G., & Keshavarzian, A.
- Affiliations
- Rush University Medical Center (US)
- Nanchang University (CN)
- University of Nebraska–Lincoln (US)
- Mercer University (US)
- Corresponding author
- Keshavarzian, Ali
- ORCID
- Venue
- Nature Communications
- Published
- 2023-02-18
- Volume
- 14
- Issue
- 1
- Pages
- 926-926
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC9938693
- OpenAlex
- W4321328855
- Cited by
- 124
- References
- 94
- Citations by year
- 2026: 24 · 2025: 55 · 2024: 35 · 2023: 10
- FWCI
- 21.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Parkinson's Foundation
- National Institutes of Health (NIH-R01, AA026801)
- National Institute on Alcohol Abuse and Alcoholism (R24AA026801)
- National Institute on Aging (R01AG056653)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Nursing › Nutrition and Dietetics › Microbial Metabolites in Food Biotechnology
- Keywords
- Parkinson's disease, prebiotic fiber, gut microbiota, short-chain fatty acids, intestinal fermentation, neuroinflammation, neurofilament light chain, dietary intervention, gut-brain axis
- MeSH terms
- Gastrointestinal Microbiome, Fatty Acids, Volatile, Feces, Humans, Parkinson Disease, Prebiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review